Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21902708 | 0.92 | MGLL (0.56) | SMN1; SMN2 | |
| SCHEMBL5108042 | 0.91 | TAAR1 (0.52) | SMN1; SMN2RAB9A | |
| SCHEMBL21902716 | 0.90 | SMN1; SMN2 (0.53) | SMN1; SMN2 | |
| SCHEMBL21902725 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9A | |
| SCHEMBL23475265 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9A | |
| SCHEMBL21902727 | 0.84 | MGLL (0.64) | — | |
| SCHEMBL1891640 | 0.84 | MGLL (0.66) | — | |
| SCHEMBL9276339 | 0.84 | TAAR1 (0.57) | RAB9A | |
| SCHEMBL18389610 | 0.84 | — | — | |
| SCHEMBL1456951 | 0.83 | MGLL (0.70) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-8372981-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-12 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7973160-B2 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | FUNAHASHI YASUHIRO | 2011-05-19 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-11-02 | — | — | US | disclosed |
| US-7109219-B2 | Nitrogen-containing aromatic derivatives | EISAI CO., LTD. (JP) | 2006-09-19 | — | — | US | disclosed |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-1522540-A1 | AZAARENE DERIVATIVES | Eisai Co., Ltd. (JP) | 2005-04-13 | — | — | EP | disclosed |
| EP-1506962-A2 | Nitrogen-containing aromatic heterocycles | Eisai Co. Ltd. (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197911-A1 | Nitrogen-Containing Aromatic Derivatives | GNG2, GCG, FRG1 | SMN1; SMN2 3996/4885L3MBTL1 2734/4885KMT2A 1207/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | SMN1; SMN2 3834/4885L3MBTL1 1149/4885KMT2A 2745/4885 |
| US-20060004029-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | SMN1; SMN2 3950/4885L3MBTL1 2633/4885KMT2A 986/4885 |
| US-20060247259-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | SMN1; SMN2 4211/4885L3MBTL1 941/4885KMT2A 2396/4885 |
| US-20110118470-A1 | NITROGEN-CONTAINING AROMATIC DERIVATIVES | GNG2, GCG, FRG1 | SMN1; SMN2 3997/4885L3MBTL1 2698/4885KMT2A 1316/4885 |
| US-20050187236-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | SMN1; SMN2 3950/4885L3MBTL1 2633/4885KMT2A 986/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | SMN1; SMN2 3950/4885L3MBTL1 2633/4885KMT2A 986/4885 |
| US-20060160832-A1 | Urea derivatives containing aromatic or heteroaromatic rings; 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide; prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | UGGT1, FLT1, GCG | SMN1; SMN2 4211/4885L3MBTL1 941/4885KMT2A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.